Choriocarcinoma: A model for tumour markers

References

• Bagshawe K D, Dent J, Webb J. Hydatidiform mole in England and Wales 1973–1983 Lancet 1986; 2: 673–7
   Google Scholar
• Bagshawe K D, Lawler S D, Paradinas F J, Dent J, Brown P, Boxer G M. Gestational trophoblastic tumours following initial diagnosis of partial hydatidiform mole. Lancet 1990; 2: 1074–6
   Google Scholar
• Wake N, Takiyi N, Susaki M. Androgenesis as a cause of hydatidiform mole. J Natl Cancer Inst 1978; 60: 51–7
   PubMedGoogle Scholar
• Ohama K. Kajii T, Okamoto E. Dispermic origin of XY hydatidiform moles. Nature 1981; 292: 551–2
   PubMed Web of Science ®Google Scholar
• Szulman A E, Surti U. The syndromes of hydatidiform mole. II: Morphological evolution of the complete and partial mole. Am J Obstet Gynecol 1978; 132: 20–7
   PubMed Web of Science ®Google Scholar
• Lawler S D, Pickthall V J, Fisher R A, Povey S, Evans M, Szulman Wyn E.A. Genetic studies on complete and partial hydatidiform moles. Lancet 1979; 2: 580
   PubMed Web of Science ®Google Scholar
• Eckstein R P, Paradinas F J, Bagshawe K D. Placental site trophoblastic tumour (trophoblastic pseudotumour): a study of four cases requiring hysterectomy including one fatal case. Histopathology 1982; 6: 211–26
   PubMedGoogle Scholar
• Kurman R J, Young R H, Norris H J, Main C S, Lawrence W D, Scully R E. Immunocytochemical localisation of placental lactogen and chorionic gonadotrophin in the normal placenta and trophoblastic tumours, with emphasis on intermediate trophoblast and the placental site trophoblastic tumour. Int J Gynecol Pathol 1984; 3: 101–21
   PubMed Web of Science ®Google Scholar
• Amano J, Sato S, Nishimura R, Mochizuki M, Kobata A. Sialic acids, but not their linkage to galactose residues, are required for full expression of the biological activity of human chorionic gonadotropin. J Biochem 1989; 105: 339–40
   PubMedGoogle Scholar
• Morgan F J, Birken S, Canfield R E. The amino acid sequence of human chorionic gonadotropin. J Biol Chem 1975; 250: 5247–58
   PubMed Web of Science ®Google Scholar
• Wehmann R E, Amr S, Rosa C, Nisula B C. Metabolism, distribution and excretion of purified human chorionic gonadotropin and its subunits in man. Ann Endocrinol 1984; 45: 291–5
   PubMed Web of Science ®Google Scholar
• O'Connor J F, Schlatterer J P, Birken S, et al. Development of highly sensitive immunoassays to measure human chorionic gonadotropin, its βsubunit and βcore fragment in the urine: Application to malignancies. Cancer Res 1988; 48: 1361–6
   PubMed Web of Science ®Google Scholar
• Nishimura R, Ide K, Utsonomiya T, Kitajama T, Yuki Y. Fragmentation of the beta sub-unit of hCG produced by choriocarcinoma. Endocrinol 1988; 123: 420–5
   PubMedGoogle Scholar
• Ozturk M, Berkowitz R, Goldstein D, Bellet D, Wands J R. Differential production of human chorionic gonadotropin and free subunits in gestational trophoblastic disease. Am J Obstet Gynecol 1988; 158: 193–8
   PubMed Web of Science ®Google Scholar
• Kardana A, Taylor M E, Southall P J, Boxer G M, Rowan A J, Bagshawe K D. Urinary gonadotrophin peptide—isolation and purification, and its immunohistochemical distribution in normal and neoplastic tissues. Br J Cancer 1988; 58: 281–6
   PubMed Web of Science ®Google Scholar
• Cole L A, Wang Y, Elliott M, et al. Urinary human chorionic gonadotropin free βsubunit and βcore fragment: A new marker of gynecological cancers. Cancer Res 1988; 48: 1356–60
   PubMed Web of Science ®Google Scholar
• Kardana A, Cole L A. Serum hCG β-core fragment is masked by associated macromolecules. J Clin Endocrinol Metab 1990; 171: 1393–5
   Google Scholar
• Kahn C R, Rosen S W, Weintraub B D, Fajans S S, Gorden P. Ectopic production of chorionic gonadotropin and its subunits by islet-cell tumours. A specific marker for malignancy. N Eng J Med 1977; 297: 565–9
   PubMed Web of Science ®Google Scholar
• Masure H R, Jaffee W L, Sickel M A, Birken S, Canfield R E, Vaitukaitis J L. Characterisation of a small molecular size urinary immunoreactive human chorionic gonadotropin (hCG) like substance produced by normal placenta and by hCG secreting neoplasms. J Clin Endocrinol Metab 1981; 53: 1014–9
   PubMed Web of Science ®Google Scholar
• Papapetrou P D, Sakarelou N P, Braouzi H, Fessas P. Ectopic production of human chorionic gonadotropin (hCG) by neoplasms: The value of measurements of immunoreactive hCG in the urine as a screening procedure. Cancer 1980; 45: 2583–92
   PubMed Web of Science ®Google Scholar
• Heitz P U, von Herbay G, Kloppel G, et al. The expression of subunits of human chorionic gonadotropin (hCG) by nontrophoblastic, nonendocrine, and endocrine tumours. Am J Clin Pathol 1987; 88: 467–72
   PubMedGoogle Scholar
• Bagshawe K D, Wilson H, Dublon P, Smith A, Baldwin M, Kardana A. Follow-up after hydatidiform mole studies using radioimmunoassay for urinary human chorionic gonadotrophin (hCG). J Obstet Gynaecol Br Cmwlth 1973; 80: 461–8
   Google Scholar
• Reyes F J, Winter J SD, Faiman C. Postpartum disappearance of chorionic gonadotropin from the maternal and neonatal circulations. Am J Obstet Gynecol 1985; 153: 486–9
   PubMedGoogle Scholar
• Franke H R, Risse E KJ, Kenemans P, Houx P CW, Stolk J G, Vooijs G P. Plasma human chorionic gonadotropin disappearance in hydatidiform mole: A central registry report from the Netherlands. Obstet Gynecol 1983; 62: 467–73
   PubMedGoogle Scholar
• Wehmann R E, Nisula B C. Metabolic and renal clearance rates of purified human chorionic gonadotropin. J Clin Invest 1981; 68: 184–93
   PubMed Web of Science ®Google Scholar
• Lurain J R, Brewer J I, Torok E E. Natural history of hydatidiform mole after primary evacuation. Am J Obstet Gynecol 1983; 145: 591–5
   PubMed Web of Science ®Google Scholar
• Stone M, Bagshawe K D. An analysis of the influences of maternal age, gestational age, contraceptive method and the mode of primary treatment of patients with hydatidiform moles on the incidence of subsequent chemotherapy. Br J Obstet Gynaecol 1979; 86: 782–92
   PubMedGoogle Scholar
• Eddy G L, Schlaerth J B, Nalick R H, Gaddis O, Jr, Nakamura R M, Morrow C P. Postmolar trophoblastic disease in women using hormonal contraception with and without estrogen. Obstet Gynecol 1983; 62: 736–40
   PubMedGoogle Scholar
• Bagshawe K D. Choriocarcinoma. Edward Arnold, London 1969
   Google Scholar
• Braunstein G D, Vaitukaitis J L, Carbone P P, Ross G T. Ectopic production of human chorionic gonadotropin by neoplasms. Ann Intern Med 1973; 78: 39–45
   PubMed Web of Science ®Google Scholar
• Bagshawe K D, Rushworth A GJ, Orr A H. The concentration of hCG in the plasma and spinal fluid of patients with trophoblastic tumours in the central nervous system. Br J Cancer 1968; 22: 253–7
   PubMedGoogle Scholar
• Bagshawe K D, Harland S. Detection of intracranial tumours with special reference to immunodiagnosis. Proc RSM 1976; 69: 51–3
   Google Scholar
• Athanassiou A, Begent R HJ, Newlands E S, Parker D, Rustin G JS, Bagshawe K D. Central nervous system metastates of choriocarcinoma: 23 years' experience at Charing Cross Hospital. Cancer 1983; 52: 1728–35
   PubMed Web of Science ®Google Scholar
• Browne P, Bagshawe K D. Enhancement of human chorionic gonadotrophin production by antimetabolites. Br J Cancer 1982; 46: 22–9
   PubMed Web of Science ®Google Scholar
• Braunstein G D, Grodin J M, Vaitukaitis J, Ross G T. Secretory rates of human chorionic gonadotropin by normal trophoblast. Am J Obstet Gynecol 1973; 115: 47–50
   Google Scholar
• Mann K, Siddle K. Evidence for free beta-subunit secretion in so-called human chorionic gonadophin-positive seminomas. Cancer 1988; 62: 2378–82
   PubMed Web of Science ®Google Scholar
• Fukayama M, Hayashi Y, Koike M. Human chorionic gonadotropin in the rectosigmoid colon. Am J Pathol 1987; 127: 83–9
   PubMedGoogle Scholar
• Odell W D, Griffin J. Pulsatile secretion of chorionic gonadotropin during the normal menstrual cycle. J Clin Endocrinol Metab 1989; 69: 528–32
   PubMed Web of Science ®Google Scholar
• Hoermann R, Spoettl G, Moncayo R, Mann K. Evidence for the presence of human chorionic gonadotropin (hCG) and free βsubunit of hCG in the human pituitary. J Clin Endocrinol Metab 1990; 71: 179–86
   PubMed Web of Science ®Google Scholar
• Begent R HJ, Bagshawe K D, Green A J, Searle F. The clinical value of imaging with antibody to human chorionic gonadotrophin in the detection of residual choriocarcinoma. Br J Cancer 1987; 55: 657–60
   PubMed Web of Science ®Google Scholar
• Bagshawe K D. Towards generating cytotoxic agents at cancer sites. The First Bagshawe Lecture. Br J Cancer 1989; 60: 275–81
   PubMed Web of Science ®Google Scholar